Minerva Neurosciences (NERV) Soars On Potential CNS Disorders Treatments; Copart (CPRT) Profits Surpass Estimates

Minerva_Neurosciences_NERV

Shares of Minerva Neurosciences, Inc. (Nasdaq:NERV) soared nearly 200% to touch a new 52-week high of $10.60 in early trade Thursday after the biopharmaceutical company said that in a Phase IIb study its MIN-101 monotherapy showed significant efficacy against negative symptoms in schizophrenia patients, while its antidepressant drug candidate MIN-117 hit its main goal in a Phase IIa clinical trial in patients with a major depressive disorder.

NERV stock is trading at $9.64, up $6.10 (or +172.29%), and 15,169,341 of its shares exchanged hands so far, representing a large increase in activity versus its average volume (3m) of 60,232

Minerva Neurosciences, focused on the development of therapies to treat central nervous system (CNS) disorders, has 27.94M Shares Outstanding and NERV stock new one-year range is from $3.45 to $10.60 per share

*

Copart_CPRT

Copart, Inc. (Nasdaq:CPRT) shares climbed to reach a new one-year high on Thursday’s trading session as the company delivered stronger-than-expected quarterly profit and revenue numbers in its financial results

For its third quarter fiscal 2016, Copart posted revenue of $347.2 million, a 16.9% increase year over year, and net income of $74.02 million, or $0.64 per diluted share, compared to net income of $57.56 million, or $0.44 per diluted share in the same quarter the prior year, topping the Capital IQ Consensus Estimate of $0.54 earnings per share on revenues of the Capital IQ Consensus of $320.52 million for the period

CPRT stock is exchanging hands at $47.88, up $3.96 (or +9.02%), and 1,445,820 shares of the company were traded so far

Copart, a provider of online auctions and vehicle remarketing services, has 112.00M Shares Outstanding and CPRT stock new 52-week range is $32.26 to $48.53 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/